A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer

BACKGROUND: Epertinib (S-222611) is a potent reversible inhibitor of HER2, EGFR and HER4. This trial evaluated the safety, tolerability, pharmacokinetics and antitumour activity of daily oral epertinib combined with trastuzumab (arm A), with trastuzumab plus vinorelbine (arm B) or with trastuzumab p...

Descripción completa

Detalles Bibliográficos
Autores principales: Macpherson, Iain R., Spiliopoulou, Pavlina, Rafii, Saeed, Saggese, Matilde, Baird, Richard D., Garcia-Corbacho, Javier, Italiano, Antoine, Bonneterre, Jacques, Campone, Mario, Cresti, Nicola, Posner, John, Takeda, Yousuke, Arimura, Akinori, Spicer, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938617/
https://www.ncbi.nlm.nih.gov/pubmed/31892325
http://dx.doi.org/10.1186/s13058-019-1178-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938617/
https://www.ncbi.nlm.nih.gov/pubmed/31892325
http://dx.doi.org/10.1186/s13058-019-1178-0

Ejemplares similares